Holen Sie sich die Stockscreener-App
32.11
7.12%
-2.46
Handel nachbörslich:
32.11
Schlusskurs vom Vortag:
$34.57
Offen:
$34.05
24-Stunden-Volumen:
921.32K
Relative Volume:
2.05
Marktkapitalisierung:
$966.81M
Einnahmen:
$1.37B
Nettoeinkommen (Verlust:
$54.85M
KGV:
18.11
EPS:
1.7729
Netto-Cashflow:
$123.71M
1W Leistung:
-11.54%
1M Leistung:
-9.52%
6M Leistung:
-19.32%
1J Leistung:
-38.53%
1-Tages-Spanne:
$31.84
$34.82
1-Wochen-Bereich:
$31.84
$36.33
52-Wochen-Spanne:
$31.84
$56.63
Conmed Corp Stock (CNMD) Company Profile
Firmenname
Conmed Corp
Sektor
Branche
Telefon
727-214-2974
Adresse
11311 CONCEPT BOULEVARD, LARGO, NY
Compare CNMD vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CNMD
Conmed Corp
|
32.11 | 1.03B | 1.37B | 54.85M | 123.71M | 1.7729 |
ABT
Abbott Laboratories
|
88.50 | 154.45B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
301.14 | 118.05B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
78.14 | 103.20B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.95 | 69.50B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.68 | 49.68B | 6.30B | 1.07B | 1.09B | 1.8406 |
Conmed Corp Stock (CNMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-17 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-06-12 | Herabstufung | Needham | Buy → Hold |
| 2025-04-28 | Herabstufung | Stifel | Buy → Hold |
| 2025-02-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-02-01 | Bestätigt | Needham | Buy |
| 2023-05-22 | Eingeleitet | CL King | Buy |
| 2023-03-27 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2023-03-21 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-03-02 | Fortgesetzt | BofA Securities | Neutral |
| 2021-10-06 | Hochstufung | Needham | Hold → Buy |
| 2021-07-15 | Eingeleitet | UBS | Buy |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2019-11-26 | Herabstufung | Needham | Buy → Hold |
| 2019-11-12 | Eingeleitet | JP Morgan | Overweight |
| 2019-10-31 | Bestätigt | Needham | Buy |
| 2019-10-04 | Bestätigt | Needham | Buy |
| 2019-08-22 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2019-04-18 | Eingeleitet | Stifel | Buy |
| 2019-04-16 | Bestätigt | Needham | Buy |
| 2019-01-23 | Bestätigt | Needham | Buy |
| 2018-10-16 | Eingeleitet | Barclays | Equal Weight |
| 2018-08-07 | Bestätigt | Needham | Buy |
| 2018-08-02 | Bestätigt | Needham | Buy |
| 2018-04-26 | Bestätigt | Needham | Buy |
| 2018-02-01 | Bestätigt | Needham | Buy |
| 2017-07-27 | Bestätigt | Needham | Buy |
| 2017-04-27 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2017-04-27 | Bestätigt | Needham | Buy |
| 2016-11-18 | Bestätigt | Needham | Buy |
| 2016-07-28 | Herabstufung | Leerink Partners | Outperform → Mkt Perform |
| 2016-04-28 | Bestätigt | Needham | Buy |
| 2015-10-22 | Bestätigt | Northland Capital | Market Perform |
Alle ansehen
Conmed Corp Aktie (CNMD) Neueste Nachrichten
Discipline and Rules-Based Execution in CNMD Response - Stock Traders Daily
CONMED Corp stock (US2074101013): Medtech mid-cap in focus after latest earnings and guidance update - AD HOC NEWS
CONMED Corp stock (US2074101013): medtech growth story after latest earnings update - AD HOC NEWS
CONMED to Repurchase $645.2 Million of 2027 Convertible Notes for $637.2 Million Cash - TradingView
CONMED (CNMD) to buy back $645.2M of 2.25% convertible notes due 2027 - Stock Titan
Director at CONMED (NYSE: CNMD) exercises 668 RSUs and receives 5,772-unit equity award - Stock Titan
CONMED (NYSE: CNMD) director gets 5,772 RSUs, converts 668 units - Stock Titan
Director at CONMED (NYSE: CNMD) receives 5,772 RSUs under 2025 incentive plan - Stock Titan
CONMED (NYSE: CNMD) director awarded 5,772 RSUs and exercises 668 into shares - Stock Titan
Director Mark Kaye receives 5,772 RSUs at CONMED (NYSE: CNMD) - Stock Titan
CONMED (NYSE: CNMD) director awarded 5,772 RSUs and converts 668 into common stock - Stock Titan
CONMED (NYSE: CNMD) interim controller details RSU and stock option holdings - Stock Titan
CONMED (CNMD) interim finance chief reports initial stock and option holdings - Stock Titan
Q1 Earnings Outperformers: CONMED (NYSE:CNMD) And The Rest Of The Surgical Equipment & ConsumablesDiversified Stocks - Yahoo Finance
CONMED Board Refresh And Governance Changes Feed Into Valuation Debate - Yahoo Finance
CONMED Corporation Executes First Omnibus Amendment and Increased Facility Activation Notice to Eighth Amended and Restated Credit Agreement - Minichart
Here's Why You Should Retain CONMED Stock in Your Portfolio Now - Yahoo Finance
Conmed secures $450 million term loan facility to repurchase convertible notes - Investing.com
Conmed Secures $450 Million Delayed-Draw Term Loan With JPMorgan to Repurchase 2026 Notes - TradingView
CONMED (NYSE: CNMD) secures $450M term loan to manage 2026 notes - Stock Titan
Why Is Conmed (CNMD) Down 3.1% Since Last Earnings Report? - Yahoo Finance
Clip Applicator Market Will Generate Booming Growth - openPR.com
(CNMD) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
CONMED Corp stock (US2074101013): focus on growth after latest quarterly results - AD HOC NEWS
CONMED Corporation Announces Results of 2026 Annual Meeting, Amended By-Laws, and Director Compensation Updates - Minichart
Conmed appoints two directors to board effective July 1 - Investing.com
Celine Martin and Jeff Mirviss join ConMed board; Kimberly Lockwood named interim controller - TradingView
New CONMED (NYSE: CNMD) directors, bylaw changes and 2026 vote outcomes - Stock Titan
J&J and Boston Scientific veterans join CONMED's board - Stock Titan
CONMED Corp stock (US2074101013): shares react to Q1 2026 results and updated full-year outlook - AD HOC NEWS
Is the Options Market Predicting a Spike in CONMED Stock? - Yahoo Finance UK
Oppenheimer Asset Management Inc. Has $1.27 Million Stock Holdings in CONMED Corporation $CNMD - MarketBeat
Does CONMED (CNMD) Refocusing Away From Gastroenterology Clarify Its Long-Term Surgical Growth Story? - Yahoo Finance
Assessing CONMED (CNMD) Valuation After A Mixed Stretch In Recent Share Performance - Yahoo Finance
Is CONMED Corporation (CNMD) A Good Stock To Buy Now? - Yahoo Finance
CNMD Q1 Deep Dive: GI Exit Refocuses Growth on Core Surgical Platforms - Yahoo Finance
CONMED (NYSE:CNMD) Stock Rating Lowered by Wall Street Zen - MarketBeat
Healthcare Momentum Story Meets NYSE Composite Trends - Kalkine Media
CONMED (NYSE:CNMD) Price Target Lowered to $39.00 at Wells Fargo & Company - MarketBeat
CNMD SEC FilingsConmed Corp 10-K, 10-Q, 8-K Forms - Stock Titan
Conmed (CNMD) Q1 2026 Earnings Transcript - AOL.com
CONMED (NYSE:CNMD) Price Target Lowered to $40.00 at JPMorgan Chase & Co. - MarketBeat
CONMED Corp 1Q 2026: Revenue $317M, EPS $0.45— 10-Q Summary - TradingView
CONMED (NYSE: CNMD) boosts Q1 2026 profit as margins expand - Stock Titan
CONMED Corporation Q1 2026 Earnings Call Summary - Yahoo Finance
CONMED's Q1 Earnings and Revenues Beat, Organic Sales Outlook Up - Yahoo Finance
Conmed Corp (CNMD) Q1 2026 Earnings Call Highlights: Navigating Challenges and Capitalizing on ... By GuruFocus - Investing.com Canada
CONMED Q1 Earnings Call Highlights - MarketBeat
CONMED (NYSE:CNMD) Releases Earnings Results, Beats Estimates By $0.07 EPS - MarketBeat
CONMED Corporation (NYSE:CNMD) Beats Q1 Estimates and Raises Revenue Guidance, Shares Steady - ChartMill
Compared to Estimates, Conmed (CNMD) Q1 Earnings: A Look at Key Metrics - Yahoo Finance
Finanzdaten der Conmed Corp-Aktie (CNMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):